Abstract: Novel 8R-antimeric and racemic 11.alpha.-methylsubstituted-prosta-5-cis, 13-trans-dienoic and prost-13-trans-enoic acids having oxygenated functions at the C-9 and C-15 positions of the molecule, as well as the 15-methyl or ethyl derivatives thereof and processes for making such compounds. Also encompassed are the pharmaceutically acceptable, non-toxic alkyl esters and salts of the carboxylic acid function of these novel compounds.

Abstract: Process for degrading the glycoside neriifolin and its acetate to the cardenolide digitoxigenin. Novel intermediates are also described.

Abstract: Novel process for the preparation of 11.alpha.-hydroxymethyl derivatives of natural (8R-) and racemic 9-keto-15.alpha.-hydroxy- and 9,15.alpha.-dihydroxy-prosta-5-cis,13-trans-dienoic and prost-13-transenoic acids, and the novel 15-methyl and ethyl substituted derivatives thereof, as well as the esters of the primary and secondary hydroxy groups and the non-toxic, pharmaceutically acceptable salts of the novel compounds.

Abstract: 10.alpha.-Hydroxy-11-desoxy-prostaglandin analogs of the PGE.sub.1 and PGE.sub.2 and PGF.sub.1.sub..alpha. and PGF.sub.2.sub..alpha. series, the 11-dehydro derivatives thereof as well as the 9,10-ketals in the PGF series, and methods of preparing same, 9-keto-10.alpha.,15.alpha.-dihydroxyprosta-13-trans-enoic or 5-cis,13-trans-dienoic acid, 9.alpha.,10.alpha.,15.alpha.-trihydroxyprosta-11,13-trans-dienoic or 5-cis, 11,13-trans-trienoic acid and 9.alpha.,10.alpha.-isopropyli-denedioxy-15.alpha.-hydroxyprosta-13-trans-e noic or 5-cis,13-trans-dienoic acid are representative of the class. Also included are the corresponding pharmaceutically acceptable, non-toxic esters, ethers and salts. These compounds possess prostaglandin-like activity and thus are useful in the treatment of mammals, where prostaglandins are indicated.